Hostname: page-component-77c89778f8-9q27g Total loading time: 0 Render date: 2024-07-16T16:40:11.129Z Has data issue: false hasContentIssue false
  • English
  • Français

Bolus application of remifentanil with propofol for dilatation and curettage

Published online by Cambridge University Press:  23 December 2004

T. Castillo ,
M. Avellanal  and
E. Garcia de Lucas
T. Castillo
Affiliation:
Hospital General Universitario Gregorio Marañón, Department of Anaesthesiology, Madrid, Spain
M. Avellanal
Affiliation:
Hospital General Universitario Gregorio Marañón, Department of Anaesthesiology, Madrid, Spain
E. Garcia de Lucas
Affiliation:
Hospital General Universitario Gregorio Marañón, Department of Anaesthesiology, Madrid, Spain
Get access

Abstract

Summary

Background and objective: This study was designed to determine which single bolus dose of remifentanil in combination with propofol and nitrous oxide is best to control the haemodynamic, autonomous and somatic responses in patients scheduled for dilatation and curettage of the uterine cervix. We evaluated the adequacy of different bolus doses of remifentanil, associated with propofol and nitrous oxide, for dilatation and curettage in a prospective double-blind study.

Methods: After institutional approval and informed consent, 34 healthy females undergoing curettage to remove material from the uterus after spontaneous abortion were randomized to receive remifentanil 0.5 μg kg−1 intravenously (i.v.) (Group A; n = 4), 1 μg kg−1 i.v. (Group B; n = 15) or 1.5 μg kg−1 i.v. (Group C; n = 15), with propofol 2 mg kg−1 i.v. in all groups. Anaesthesia was maintained with 60% nitrous oxide in oxygen. Haemodynamic, somatic and autonomic signs of light anaesthesia were registered to assess the response to surgical stress. Recovery times and Aldrete score were recorded at the end of the procedure.

Results: The groups were similar with regard to biometric data and duration of surgery. The poor results using the lowest dose of remifentanil obliged us to abandon this dose. The total dose of remifentanil was larger in Group C (100 ± 5.7 μg vs. 65 ± 4.1 μg in Group B; P < 0.05), but more patients required extra bolus injections in Group B (69% vs. 38% in Group C; P < 0.01). Recovery times were significantly shorter in Group C. Aldrete scores when leaving the operation room was similar.

Conclusions: Remifentanil 1.5 μg kg−1 i.v. with propofol 2 mg kg−1 i.v. and 60% nitrous oxide in oxygen provided the best anaesthetic control with the fastest recovery times.

Keywords

NARCOTICS, opioid, remifentanilSURGICAL PROCEDURESOPERATIVE, curettage, dilatation and curettage
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 21 , Issue 5 , May 2004 , pp. 408 - 411
Copyright
2004 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Burkle H, Dunbar S, van Aken H. Remifentanil: a novel, short-acting, mu-opioid. Anesth Analg 1996; 83: 646–651.Google Scholar
Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartiment pharmacokinetics models for intravenous anesthetic drugs. Anesthesiology 1992; 76: 334–341.Google Scholar
O'Hare R, McAtamney D, Mirakhur RK, Hughes D, Carabine V. Bolus dose of remifentanil for control of hemodynamic response to tracheal intubation during rapid sequence induction of anesthesia. Br J Anaesth 1999; 82: 283–285.Google Scholar
McNeil IA, Culbert B, Russell I. Comparison of intubating conditions following propofol and succinylcholine versus propofol and remifentanil 2 micrograms kg−1 or 4 micrograms kg−1. Br J Anaesth 2000; 85: 623–625.Google Scholar
Sá Rêgo MM, Inagaki Y, White PF. Remifentanil administration during monitored anesthesia care: are intermittent boluses an effective alternative to a continous infusion? Anesth Analg 1999; 88: 518–522.Google Scholar
Dershwitz M, Randel GI, Rosow CE, et al. Initial clinical experience with remifentanil, a new opioid metabolized by esterases. Anesth Analg 1995; 81: 619–623.Google Scholar
Hogue JrCW, Bowdle TA, O'Leary C, et al. A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Anesth Analg 1996; 83: 279–285.Google Scholar
Song D, Whitten CW, White PF. Use of remifentanil during anesthetic induction: a comparison with fentanyl in the ambulatory setting. Anesth Analg 1999; 88: 734–736.Google Scholar